TWO-THIRDS OF HEART FAILURE PATIENTS WHO MEET THE FDA-APPROVED INDICATION FOR SACUBITRIL/VALSARTAN DO NOT MEET PARADIGM-HF ENROLLMENT CRITERIA AFTER RECENT HOSPITALIZATION

Abstract

The angiotensin-neprilysin inhibitor sacubitril/valsartan was approved by FDA for NYHA FC II-IV chronic heart failure (HF) patients with reduced ejection fraction (HFrEF) based on the PARADIGM-HF trial, which excluded patients with low GFR, low baseline BP, and ACE inhibitor (ACE-I) and beta blocker